For example, the GLP-1 receptor agonist semaglutide has been shown to promote insulin secretion, improve cardiac metabolism, and reduce myocardial injury, thus delaying the progression of DCM (111). This evidence concerns the gene GLP1R and familial dilated cardiomyopathy.